Scroll to top

Scroll to top

News Releases

News Releases

Month Year

Month Year

Investor Alerts

Sep 29, 2020

Immunic, Inc. to Participate in Scientific Conferences in October
Sep 28, 2020

Immunic, Inc. Announces Results From Interim Safety Analysis and Recruitment Update From Its Ongoing Phase 2 CALVID-1 Trial of IMU-838 in Patients With Moderate COVID-19
Sep 11, 2020

Immunic, Inc. Publishes Full Unblinded Clinical Data From Phase 2 EMPhASIS Trial of IMU-838 in Patients With Relapsing-Remitting Multiple Sclerosis and Announces Poster Presentation at the MSVirtual2020

- Unblinded Subgroup Analyses Show Consistent Effect for MRI Lesion Suppression Across Different Populations -
Sep 8, 2020

Immunic, Inc. to Participate in Scientific and Investor Conferences in September
Aug 20, 2020

Immunic, Inc. Announces Dosing of First Healthy Volunteer in Phase 1 Clinical Program of IMU-856, Targeting Restoration of Intestinal Barrier Function
Aug 10, 2020

Immunic, Inc. Announces Closing of $103.5 Million Public Offering, including Full Exercise of Underwriters' Option to Purchase Additional Shares
Aug 4, 2020

Immunic, Inc. Announces Pricing of $90.0 Million Public Offering of Common Stock
Aug 3, 2020

Immunic, Inc. Announces Proposed Public Offering of 5 Million Shares of Common Stock
Aug 2, 2020

Immunic, Inc. Reports Positive Top-line Data from Phase 2 EMPhASIS Trial of IMU-838 in Patients with Relapsing-Remitting Multiple Sclerosis

- Study Meets Primary and Key Secondary Endpoints with High Statistical Significance Indicating Activity for IMU-838 in Relapsing-Remitting Multiple Sclerosis -
Jul 30, 2020

Immunic, Inc. to Report Second Quarter 2020 Financial Results and Provide Corporate Update

Show per page